Core Scientific (CORZ) officer pre-planned sale, still holds 2.09M shares

Rhea-AI Filing Summary

Core Scientific, Inc. officer Todd M. Duchene reported an open-market sale of 10,000 shares of Common Stock on May 26, 2026 at a weighted average price of $26.254 per share. The transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating they were pre-scheduled. After these sales, Duchene directly holds 2,088,895 shares, so the sale represents a relatively small portion of his overall position. The shares were sold in multiple trades at prices ranging from $25.81 to $26.75.

Insights

Equity markets and insider-trading analyst

Routine 10b5-1 sale of a small portion of holdings.

Officer Todd M. Duchene sold 10,000 shares of Core Scientific common stock at a weighted average price of $26.254 per share. The filing shows this was an open-market sale rather than an option exercise or compensation event.

The sale occurred under a Rule 10b5-1 trading plan adopted on December 5, 2025, meaning the trades were pre-scheduled rather than timed opportunistically. After the sale, Duchene still holds 2,088,895 shares, so the transaction reflects only a small fraction of his disclosed stake.

Given the pre-planned nature and modest size relative to total holdings, this looks like routine liquidity management. The filing does not describe any remaining derivatives, suggesting the visible position is entirely common stock as of the reported date.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares ($262,540)

Net Sell 1 txn

Insider DUCHENE TODD M

Role See remarks

Sold 10,000 shs ($263K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$26.254	$263K

Holdings After Transaction: Common Stock — 2,088,895 shares (Direct, null)

Footnotes (1)

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.81 to $26.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Key Figures

Shares sold: 10,000 shares Weighted average sale price: $26.254 per share Post-transaction holdings: 2,088,895 shares +2 more

5 metrics

Shares sold 10,000 shares Open-market sale on May 26, 2026

Weighted average sale price $26.254 per share Common Stock sale

Post-transaction holdings 2,088,895 shares Shares directly held after sale

Sale price range $25.81–$26.75 per share Multiple trades within this range

10b5-1 plan adoption date December 5, 2025 Effective trading plan for reported sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUCHENE TODD M

(Last) (First) (Middle)

C/O CORE SCIENTIFIC, INC.

838 WALKER ROAD, SUITE 21-2105

(Street)

DOVER DELAWARE 19904

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/26/2026		S(1)		10,000	D	$26.254(2)	2,088,895	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.81 to $26.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Remarks:

Chief Legal and Administrative Officer

	/s/ Todd DuChene	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Core Scientific (CORZ) officer Todd M. Duchene report in this Form 4?

Todd M. Duchene reported selling 10,000 shares of Core Scientific common stock. The open-market sale occurred on May 26, 2026, at a weighted average price of $26.254 per share, and was executed under a pre-established Rule 10b5-1 trading plan.

At what prices did Todd M. Duchene sell Core Scientific (CORZ) shares?

The reported weighted average sale price was $26.254 per share. According to the filing, individual trades occurred in a range from $25.81 to $26.75 per share, with the officer offering to provide exact trade breakdowns on request.

How many Core Scientific (CORZ) shares does Todd M. Duchene hold after the sale?

After selling 10,000 shares, Todd M. Duchene directly holds 2,088,895 Core Scientific common shares. This indicates the transaction involved only a small portion of his overall reported position in the company’s stock.

Was the Core Scientific (CORZ) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted on December 5, 2025, meaning the trades were pre-scheduled rather than discretionary at the time of execution.

What type of transaction did Todd M. Duchene report for Core Scientific (CORZ)?

The Form 4 reports an open-market sale of common stock, coded as “S.” This indicates a straightforward sale transaction, not an option exercise, tax withholding, gift, or derivative-related event in this particular filing.